Ironwood Pharmaceuticals (IRWD) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Ironwood Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$351.41M

Latest Revenue (Q)

$91.59M

Main Segment (Y)

Collaborative arrangements revenue

Main Geography (Y)

North America

Ironwood Pharmaceuticals Revenue by Period

Ironwood Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$351.41M	-20.63%
2023-12-31	$442.74M	7.83%
2022-12-31	$410.60M	-0.76%
2021-12-31	$413.75M	6.22%
2020-12-31	$389.52M	-9.08%
2019-12-31	$428.41M	23.59%
2018-12-31	$346.64M	16.21%
2017-12-31	$298.28M	8.88%
2016-12-31	$273.96M	83.18%
2015-12-31	$149.56M	95.66%
2014-12-31	$76.44M	234.06%
2013-12-31	$22.88M	-84.77%
2012-12-31	$150.25M	128.09%
2011-12-31	$65.87M	50.19%
2010-12-31	$43.86M	21.48%
2009-12-31	$36.10M	62.50%
2008-12-31	$22.22M	112.31%
2007-12-31	$10.46M	233.25%
2006-12-31	$3.14M	-

Ironwood Pharmaceuticals generated $351.41M in revenue during NA 2024, up -20.63% compared to the previous quarter, and up 82.03% compared to the same period a year ago.

Ironwood Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2024-09-30	$91.59M	-2.97%
2024-06-30	$94.40M	26.07%
2024-03-31	$74.88M	-36.30%
2023-12-31	$117.55M	3.35%
2023-09-30	$113.74M	5.92%
2023-06-30	$107.38M	3.19%
2023-03-31	$104.06M	-2.93%
2022-12-31	$107.20M	-1.32%
2022-09-30	$108.64M	11.73%
2022-06-30	$97.23M	-0.31%
2022-03-31	$97.53M	-16.73%
2021-12-31	$117.13M	12.90%
2021-09-30	$103.75M	-0.27%
2021-06-30	$104.03M	17.09%
2021-03-31	$88.84M	-23.86%
2020-12-31	$116.68M	12.77%
2020-09-30	$103.47M	15.69%
2020-06-30	$89.43M	11.87%
2020-03-31	$79.94M	-36.70%
2019-12-31	$126.30M	-3.71%
2019-09-30	$131.17M	28.32%
2019-06-30	$102.22M	48.72%
2019-03-31	$68.73M	-47.41%
2018-12-31	$130.69M	98.96%
2018-09-30	$65.69M	-19.01%
2018-06-30	$81.11M	17.28%
2018-03-31	$69.16M	-26.59%
2017-12-31	$94.21M	8.50%
2017-09-30	$86.83M	33.42%
2017-06-30	$65.08M	24.75%
2017-03-31	$52.17M	-40.35%
2016-12-31	$87.46M	32.30%
2016-09-30	$66.11M	21.63%
2016-06-30	$54.35M	-17.70%
2016-03-31	$66.04M	23.89%
2015-12-31	$53.31M	34.71%
2015-09-30	$39.57M	42.63%
2015-06-30	$27.74M	-4.11%
2015-03-31	$28.93M	-24.01%
2014-12-31	$38.07M	125.04%
2014-09-30	$16.92M	147.34%
2014-06-30	$6.84M	-53.17%
2014-03-31	$14.61M	190.30%
2013-12-31	$5.03M	2.01%
2013-09-30	$4.93M	-48.96%
2013-06-30	$9.66M	196.87%
2013-03-31	$3.25M	-87.94%
2012-12-31	$26.98M	-72.02%
2012-09-30	$96.41M	560.18%
2012-06-30	$14.60M	19.24%
2012-03-31	$12.25M	-61.91%
2011-12-31	$32.15M	163.17%
2011-09-30	$12.22M	8.49%
2011-06-30	$11.26M	10.01%
2011-03-31	$10.24M	-38.96%
2010-12-31	$16.77M	85.14%
2010-09-30	$9.06M	-17.34%
2010-06-30	$10.96M	21.07%
2010-03-31	$9.05M	5.21%
2009-12-31	$8.60M	-43.61%
2009-09-30	$15.26M	130.82%
2009-06-30	$6.61M	26.36%
2009-03-31	$5.23M	5.17%
2008-12-31	$4.97M	-

Ironwood Pharmaceuticals generated $91.59M in revenue during Q3 2024, up -2.97% compared to the previous quarter, and up 85.30% compared to the same period a year ago.

Ironwood Pharmaceuticals Revenue Breakdown

Ironwood Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Collaborative arrangement, collaboration and license agreements	$1.67M	$1.80M	$635.00K	$743.00K	-
Royalty	$400.00K	$2.20M	$100.00K	-	-
Collaborative arrangement, other agreements	$734.00K	$2.48M	$1.82M	$1.75M	-
Collaborative arrangements revenue	$351.41M	$442.74M	$410.60M	$412.78M	-
Collaborative arrangement, co-promotion agreements	$2.25M	$2.01M	$2.19M	$2.41M	-
Sale of active pharmaceutical ingredient	-	-	-	$969.00K	-
Collaborative Arrangement Collaboration And License Agreements Upfront Fee	-	-	-	-	$10.00M
Collaborative Arrangement Collaboration Agreements	-	-	-	-	$32.40M
Collaborative Arrangement Collaboration And License Agreements	-	-	-	-	$700.00K
Collaborative Arrangement Transition Services Agreement	-	-	-	-	$600.00K
Collaborative Arrangement Co Promotion Agreement	-	-	-	-	$4.30M
Collaborative Arrangement Promotion Agreement	-	-	-	-	$3.50M

Ironwood Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaborative arrangements revenue (98.58%), Collaborative arrangement, co-promotion agreements (0.63%), Collaborative arrangement, collaboration and license agreements (0.47%), Collaborative arrangement, other agreements (0.21%), and Royalty (0.11%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Royalty	-	$700.00K	$100.00K	$300.00K	$200.00K	$200.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaborative arrangement, other agreements	-	$222.00K	$516.00K	$580.00K	$570.00K	$365.00K	$409.00K	$480.00K	$396.00K	$547.00K	$408.00K	-	-	-	-	-	-	-	-	-
Collaborative arrangement, collaboration and license agreements	$892.00K	$413.00K	$368.00K	$121.00K	$91.00K	$151.00K	$144.00K	$148.00K	$192.00K	$114.00K	$219.00K	$200.00K	-	-	-	-	-	-	-	-
Collaborative arrangements revenue	-	-	-	$107.38M	$104.06M	$107.20M	$108.64M	$97.23M	$97.53M	$116.99M	$103.75M	$103.39M	-	-	-	-	-	-	-	-
Collaborative arrangement, co-promotion agreements	-	-	-	-	-	-	$814.00K	$585.00K	$823.00K	$676.00K	$683.00K	$596.00K	-	-	-	-	-	-	-	-
Sale of active pharmaceutical ingredient	-	-	-	-	-	-	-	-	-	$144.00K	$645.00K	-	-	-	-	-	-	-	-	-
Collaborative Arrangement Transition Services Agreement	-	-	-	-	-	-	-	-	-	-	-	-	$100.00K	-	-	-	-	-	-	-
Active Pharmaceutical Ingredient	-	-	-	-	-	-	-	-	-	-	-	-	$180.00K	$20.65M	$643.00K	$24.89M	-	-	-	-
Collaborative Arrangement Collaboration And License Agreements	-	-	-	-	-	-	-	-	-	-	-	-	$200.00K	-	-	-	-	-	-	-
Collaborative Arrangements	-	-	-	-	-	-	-	-	-	-	-	-	$88.67M	$105.65M	$130.52M	$77.32M	-	-	-	-
Collaborative Arrangement Promotion Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	$400.00K	$1.10M	$1.10M	$900.00K	$2.30M	-	-
Collaborative Arrangement Co Promotion Agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.20M	$1.10M	$1.06M	$1.28M	$2.60M	$1.24M	-
License And Service	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$900.00K	$900.00K	$900.00K	-	-	-
Collaborative Arrangement Co Promotion And Other Agreements	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$945.00K	$500.00K	-	-
Collaborative Arrangement Other Agreements	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$229.00K	$346.00K	$323.00K

Ironwood Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaborative arrangement, collaboration and license agreements (100.00%).

Ironwood Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Europe and Other	$3.24M	$2.80M	$2.40M	$2.60M	-
North America	$343.15M	$433.24M	$2.73M	$2.71M	$2.30M
Canada and Mexico	-	-	$2.70M	$2.70M	-
Canada And Mexico	-	-	-	-	$2.30M
U	-	-	-	-	$368.60M
Europe And Other	-	-	-	-	$2.20M
Europe	-	-	-	-	$2.20M

Ironwood Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: North America (99.07%), and Europe and Other (0.93%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Europe and Other	$1.72M	$807.00K	$706.00K	$597.00K	$702.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
North America	$181.27M	$89.43M	$72.45M	$431.81M	$731.00K	$700.00K	$679.00K	$861.00K	$609.00K	$582.00K	$765.00K	$668.00K	$731.00K	$550.00K	$605.00K	$721.00K	$423.00K	$550.00K	$603.00K	-
Canada and Mexico	-	-	-	-	$700.00K	$700.00K	$600.00K	$900.00K	$600.00K	$600.00K	$800.00K	$700.00K	$700.00K	-	-	-	-	-	-	-
Canada And Mexico	-	-	-	-	-	-	-	-	-	-	-	-	-	$600.00K	$600.00K	$700.00K	$400.00K	$600.00K	$600.00K	-
Europe	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$600.00K	$500.00K	$400.00K	$600.00K	$500.00K	-
Europe And Other	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$603.00K	$510.00K	$440.00K	$643.00K	$510.00K	$526.00K
China Hong Kong And Macau	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$100.00K	$200.00K	$200.00K	$227.00K	$32.40M
J	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$500.00K	$500.00K	$400.00K	$88.00K	$10.06M
U	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$71.14M	$101.60M	-

Ironwood Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 24: North America (99.06%), and Europe and Other (0.94%).

Ironwood Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
NBIX	Neurocrine Biosciences	$2.36B	$622.10M
ALKS	Alkermes	$1.56B	$378.14M
AMPH	Amphastar Pharmaceuticals	$712.81M	$188.82M
PCRX	Pacira BioSciences	$700.97M	$168.57M
ITCI	Intra-Cellular Therapies	$680.85M	$175.38M
COLL	Collegium Pharmaceutical	$631.45M	$159.30M
ANIP	ANI Pharmaceuticals	$614.38M	$148.33M
IRWD	Ironwood Pharmaceuticals	$351.41M	$91.59M
ESPR	Esperion Therapeutics	$332.31M	$51.63M
AVDL	Avadel Pharmaceuticals	$169.12M	$50.02M
ASRT	Assertio	$124.96M	$29.20M

IRWD Revenue FAQ

What is Ironwood Pharmaceuticals’s yearly revenue?

Ironwood Pharmaceuticals's yearly revenue for 2024 was $351.41M, representing a decrease of -20.63% compared to 2023. The company's yearly revenue for 2023 was $442.74M, representing an increase of 7.83% compared to 2022. IRWD's yearly revenue for 2022 was $410.6M, representing a decrease of -0.76% compared to 2021.

What is Ironwood Pharmaceuticals’s quarterly revenue?

Ironwood Pharmaceuticals's quarterly revenue for Q3 2024 was $91.59M, a -2.97% decrease from the previous quarter (Q2 2024), and a -19.47% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $94.4M, a 26.07% increase from the previous quarter (Q1 2024), and a -12.09% decrease year-over-year (Q2 2023). IRWD's quarterly revenue for Q1 2024 was $74.88M, a -36.30% decrease from the previous quarter (Q4 2023), and a -28.05% decrease year-over-year (Q1 2023).

What is Ironwood Pharmaceuticals’s revenue growth rate?

Ironwood Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was -14.41%, and for the last 5 years (2020-2024) was -9.78%.

What are Ironwood Pharmaceuticals’s revenue streams?

Ironwood Pharmaceuticals's revenue streams in c 24 are Collaborative arrangement, collaboration and license agreements, Royalty, Collaborative arrangement, other agreements, Collaborative arrangements revenue, and Collaborative arrangement, co-promotion agreements. Collaborative arrangement, collaboration and license agreements generated $1.67M in revenue, accounting 0.47% of the company's total revenue, down -7.00% year-over-year. Royalty generated $400K in revenue, accounting 0.11% of the company's total revenue, down -81.82% year-over-year. Collaborative arrangement, other agreements generated $734K in revenue, accounting 0.21% of the company's total revenue, down -70.36% year-over-year. Collaborative arrangements revenue generated $351.41M in revenue, accounting 98.58% of the company's total revenue, down -20.63% year-over-year. Collaborative arrangement, co-promotion agreements generated $2.25M in revenue, accounting 0.63% of the company's total revenue, up 11.95% year-over-year.

What is Ironwood Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Ironwood Pharmaceuticals was Collaborative arrangements revenue. This segment made a revenue of $351.41M, representing 98.58% of the company's total revenue.